Kidney and Metabolic Phenotypes in Glycogen Storage Disease Type-I Patients

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2020 Oct 12

PMID 33042926

Citations 6

Authors

Bilal Aoun

Sami Sanjad

Jad A Degheili

Abir Barhoumi

Amina Bassyouni

Pascale E Karam

Affiliations

Soon will be listed here.

Abstract

A retrospective chart review of 32 GSD- I patients, followed at the American University of Beirut Medical Center, between 2007 and 2018 was conducted. Diagnosis was confirmed by enzymatic and/or genetic studies. Clinical presentation, growth, and kidney outcome were assessed. All patients were evaluated for body mass index, blood parameters of metabolic control including uric acid, alanine, lactic acid, and triglycerides in blood. Kidney evaluation included creatinine clearance, microalbuminuria, citraturia, and calciuria as well as urine microalbumin/creatinine ratio. Almost one third of GSD-I patients developed microalbuminuria. This was detected below 7 months of age in 36% of patients who required early treatment with ACEI with significant reduction in albuminuria. Kidney stones were present in 6% and were associated with hypercalciuria and hypocitraturia. Poor metabolic control reflected by hyperuricemia, lactic acidosis, and hyperalaninemia were noted only in patients who developed microalbuminuria. Glomerular injury may appear in early infancy in poorly controlled patients. Adequate metabolic control and ACEI therapy may improve kidney outcome in GSD I patients. Plasma alanine appears to be a promising and reliable marker reflecting metabolic control in GSD-I patients.

Citing Articles

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near.

Portalatin G, Hong-McAtee I, Burgner A, Gould E, Hunley T Front Pediatr. 2025; 13:1521425.

PMID: 39950157 PMC: 11821607. DOI: 10.3389/fped.2025.1521425.

Glycogen storage disease type I: Genetic etiology, clinical manifestations, and conventional and gene therapies.

Zhong J, Gou Y, Zhao P, Dong X, Guo M, Li A Pediatr Discov. 2024; 1(2).

PMID: 38370424 PMC: 10874634. DOI: 10.1002/pdi3.3.

Clinical and biochemical footprints of inherited metabolic diseases. XIV. Metabolic kidney diseases.

Schumann A, Schultheiss U, Ferreira C, Blau N Mol Genet Metab. 2023; 140(3):107683.

PMID: 37597335 PMC: 11747985. DOI: 10.1016/j.ymgme.2023.107683.

Clinical and genetic spectrum of GSD type 6 in Korea.

Hahn J, Lee H, Seong M, Kang G, Moon J, Ko J Orphanet J Rare Dis. 2023; 18(1):132.

PMID: 37264426 PMC: 10233917. DOI: 10.1186/s13023-023-02750-1.

Treatment of the Neutropenia Associated with GSD1b and G6PC3 Deficiency with SGLT2 Inhibitors.

Veiga-da-Cunha M, Wortmann S, Grunert S, Van Schaftingen E Diagnostics (Basel). 2023; 13(10).

PMID: 37238286 PMC: 10217388. DOI: 10.3390/diagnostics13101803.

References

Chou J, Cho J, Kim G, Mansfield B . Molecular biology and gene therapy for glycogen storage disease type Ib. J Inherit Metab Dis. 2018; 41(6):1007-1014. DOI: 10.1007/s10545-018-0180-5. View

Chen Y, Van Hove J . Renal involvement in type I glycogen storage disease. Adv Nephrol Necker Hosp. 1995; 24:357-65. View

Chen S, Pan C, Lee S, Peng W, Chou J . Functional analysis of mutations in the glucose-6-phosphate transporter that cause glycogen storage disease type Ib. Mol Genet Metab. 2008; 95(4):220-3. PMC: 3422630. DOI: 10.1016/j.ymgme.2008.08.005. View

Chou J, Jun H, Mansfield B . Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes. J Inherit Metab Dis. 2014; 38(3):511-9. DOI: 10.1007/s10545-014-9772-x. View

Choi R, Park H, Ko J, Lee J, Lee D, Hong S . Novel SLC37A4 Mutations in Korean Patients With Glycogen Storage Disease Ib. Ann Lab Med. 2017; 37(3):261-266. PMC: 5339099. DOI: 10.3343/alm.2017.37.3.261. View

Okechuku G, Shoemaker L, Dambska M, Brown L, Mathew J, Weinstein D . Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy. J Inherit Metab Dis. 2017; 40(5):703-708. DOI: 10.1007/s10545-017-0054-2. View

Palatini P . Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant. 2012; 27(5):1708-14. DOI: 10.1093/ndt/gfs037. View

Restaino I, Kaplan B, Stanley C, Baker L . Nephrolithiasis, hypocitraturia, and a distal renal tubular acidification defect in type 1 glycogen storage disease. J Pediatr. 1993; 122(3):392-6. DOI: 10.1016/s0022-3476(05)83422-5. View

Chen Y, Scheinman J, Park H, Coleman R, Roe C . Amelioration of proximal renal tubular dysfunction in type I glycogen storage disease with dietary therapy. N Engl J Med. 1990; 323(9):590-3. DOI: 10.1056/NEJM199008303230907. View

10.

Santos B, de Souza C, Schuler-Faccini L, Refosco L, Epifanio M, Nalin T . Glycogen storage disease type I: clinical and laboratory profile. J Pediatr (Rio J). 2014; 90(6):572-9. DOI: 10.1016/j.jped.2014.02.005. View

11.

Dambska M, Labrador E, Kuo C, Weinstein D . Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control. Pediatr Diabetes. 2017; 18(5):327-331. DOI: 10.1111/pedi.12540. View

12.

Rake J, Visser G, Labrune P, Leonard J, Ullrich K, Smit G . Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002; 161 Suppl 1:S20-34. DOI: 10.1007/s00431-002-0999-4. View

13.

Santer R, Rischewski J, Block G, Kinner M, Wendel U, Schaub J . Molecular analysis in glycogen storage disease 1 non-A: DHPLC detection of the highly prevalent exon 8 mutations of the G6PT1 gene in German patients. Hum Mutat. 2000; 16(2):177. DOI: 10.1002/1098-1004(200008)16:2<177::AID-HUMU13>3.0.CO;2-8. View

14.

Ng E, Gupta S, Khin S, Mak A . Gout, anemia, and hepatomegaly in a young man with glycogen storage disease. J Clin Rheumatol. 2012; 18(4):222-3. DOI: 10.1097/RHU.0b013e3182598ed1. View

15.

Melis D, Fulceri R, Parenti G, Marcolongo P, Gatti R, Parini R . Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature. Eur J Pediatr. 2005; 164(8):501-8. DOI: 10.1007/s00431-005-1657-4. View

16.

Visser G, Rake J, Labrune P, Leonard J, Moses S, Ullrich K . Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. Eur J Pediatr. 2002; 161 Suppl 1:S120-3. DOI: 10.1007/s00431-002-1017-6. View

17.

Kishnani P, Austin S, Abdenur J, Arn P, Bali D, Boney A . Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014; 16(11):e1. DOI: 10.1038/gim.2014.128. View

18.

Martens D, Rake J, Navis G, Fidler V, van Dael C, Smit G . Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition. Clin J Am Soc Nephrol. 2009; 4(11):1741-6. PMC: 2774963. DOI: 10.2215/CJN.00050109. View

19.

Melis D, Parenti G, Gatti R, Della Casa R, Parini R, Riva E . Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin Endocrinol (Oxf). 2005; 63(1):19-25. DOI: 10.1111/j.1365-2265.2005.02292.x. View

20.

Stroppiano M, Regis S, Dirocco M, Caroli F, Gandullia P, Gatti R . Mutations in the glucose-6-phosphatase gene of 53 Italian patients with glycogen storage disease type Ia. J Inherit Metab Dis. 1999; 22(1):43-9. DOI: 10.1023/a:1005495131118. View